CLINICAL TRIALS PROFILE FOR VERELAN

All Clinical Trials for VERELAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00589303 ↗	AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study	Terminated	Medtronic	Phase 3	2007-12-01	The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT00589303 ↗	AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study	Terminated	Mayo Clinic	Phase 3	2007-12-01	The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT01467687 ↗	Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions	Completed	Synerx Pharma, LLC	Phase 1	2007-07-01	The purpose of this study is to determine the bioequivalency of Synerx Pharma Verapamil extended release capsules.
NCT00648050 ↗	Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-03-01	The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following evening administration of a single, oral 300 mg (1 x 300 mg) dose administration under fasting conditions.
NCT00647673 ↗	Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-01-01	The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following evening administration of a single, oral 300 mg (1 x 300 mg) dose under fasting conditions.
NCT00648401 ↗	Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-01-01	The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following a single, oral 300 mg (1 x 300 mg) dose administration under fed conditions.
NCT00649805 ↗	Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-01-01	The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following by a single, oral 300 mg (1 x 300 mg) dose administration sprinkled on one tablespoon of applesauce under fasting conditions.

Clinical Trial Conditions for VERELAN

Condition Name

Condition Name for VERELAN
Intervention	Trials
Healthy	5
Recurrent Hodgkin Lymphoma	1
Atrial Fibrillation	1
Refractory Hodgkin Lymphoma	1

Condition MeSH

Condition MeSH for VERELAN
Intervention	Trials
Ischemic Stroke	1
Hemorrhage	1
Atrial Fibrillation	1
Ischemia	1

Clinical Trial Locations for VERELAN

Trials by Country

+

−

Trials by Country for VERELAN
Location	Trials
United States	15
Canada	1

Trials by US State

+

−

Trials by US State for VERELAN
Location	Trials
North Dakota	4
Minnesota	2
Oregon	1
Indiana	1
Arizona	1

Clinical Trial Progress for VERELAN

Clinical Trial Phase

Clinical Trial Phase for VERELAN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1	8

Clinical Trial Status

Clinical Trial Status for VERELAN
Clinical Trial Phase	Trials
Completed	8
Not yet recruiting	2
Recruiting	1

Clinical Trial Sponsors for VERELAN

Sponsor Name

Sponsor Name for VERELAN
Sponsor	Trials
Mylan Pharmaceuticals	4
Mayo Clinic	2
Assiut University	2

Sponsor Type

Sponsor Type for VERELAN
Sponsor	Trials
Other	11
Industry	7
NIH	1

VERELAN (Verapamil Hydrochloride): Clinical Trials, Market Analysis, and Projections

Introduction to VERELAN

VERELAN, also known as verapamil hydrochloride, is a calcium channel blocker used primarily for the treatment of hypertension, angina pectoris, and certain types of arrhythmias. Here, we will delve into the latest clinical trials, market analysis, and projections for this medication.

Clinical Trials and Efficacy

While there are no recent Phase 1 or Phase 3 clinical trials specifically focused on VERELAN, existing studies and clinical data provide valuable insights into its efficacy and safety.

Efficacy in Hypertension and Cardiovascular Conditions

Verapamil hydrochloride has been extensively studied and is well-established for its efficacy in lowering blood pressure and managing cardiovascular conditions. Clinical trials have shown that verapamil reduces the risk of fatal and nonfatal cardiovascular events, such as strokes and myocardial infarctions[3].

Impact on Pancreatic Beta Cell Function

An interesting recent study published in JAMA explored the effect of verapamil on pancreatic beta cell function in patients with type 1 diabetes. The study found a 30% improvement in C-peptide secretion over one year, indicating potential benefits for pancreatic function[4].

Market Analysis

Global Market Size and Growth

The global verapamil hydrochloride market is anticipated to experience significant growth. By 2027, the market is projected to reach USD 2.5 billion, growing at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2027. This growth is driven by increasing demand for cardiovascular drugs and rising incidences of hypertension and arrhythmias worldwide[5].

Regional Market Trends

• North America: This region, particularly the United States, is expected to play a pivotal role in the market's development. The presence of major industry players and the adoption of advanced technologies are key drivers of growth in this region[5].
• Europe: Europe is also expected to experience significant growth, with a strong CAGR during the forecast period from 2024 to 2031. The region's robust healthcare infrastructure and high demand for cardiovascular treatments contribute to this growth[5].

Distribution Channels and Consumer Trends

The rise of e-commerce and direct-to-consumer (D2C) sales channels has transformed the distribution landscape for verapamil hydrochloride. Online platforms provide consumers with convenient access to medications, offering cost advantages and a more personalized purchasing experience. This shift is expected to expand the market reach and provide greater consumer access to verapamil hydrochloride[5].

Key Manufacturers and Market Share

Several companies are prominent in the verapamil hydrochloride market:

• Bharat Pharmaceuticals
• Titan Pharma (India) Pvt Ltd
• Vpl Chemicals Pvt Ltd
• Wuhan Fortuna Chemical Co., Ltd
• Abbott
• Boc Sciences
• Chemische Fabrik Weyl Gmbh
• Chinoin Pharmaceutical And Chemical Works Co Ltd
• Divis Laboratories Ltd
• Drug'on Pharma Switzerland AG
• Fermion Oy
• Fine Chemicals Corp
• Piramal Enterprises Limited

These companies are focusing on strategies to strengthen their product portfolios and expand their business in the global market[5].

Market Segments and Applications

The verapamil hydrochloride market is segmented based on type and application:

• Tablet: This segment is expected to expand significantly during the forecast period, retaining its position as a dominant form of the medication[5].
• Injectable: While less common, injectable forms of verapamil hydrochloride also hold a significant market share, particularly in acute settings[5].

Projections and Future Outlook

Market Size and Revenue

The global verapamil hydrochloride market is projected to continue growing, driven by increasing demand and the rising incidence of cardiovascular diseases. By 2031, the market is expected to show substantial growth, with North America and Europe leading the way[5].

Technological and Regulatory Trends

Advances in pharmaceutical technology and changes in regulatory environments are expected to influence the market. For instance, the integration of digital health solutions and personalized medicine could further enhance the market's growth potential[5].

Safety and Pharmacokinetics

Verapamil hydrochloride is generally well-tolerated, but it requires careful dosing, especially in elderly patients or those with hepatic or renal impairment. The medication is highly metabolized by the liver, and about 70% of the administered dose is excreted as metabolites in the urine. Food does not affect the absorption of verapamil from controlled-release formulations[3].

Key Takeaways

• Clinical Efficacy: Verapamil hydrochloride is effective in treating hypertension and other cardiovascular conditions, with potential benefits for pancreatic beta cell function.
• Market Growth: The global market is projected to reach USD 2.5 billion by 2027, driven by increasing demand and technological advancements.
• Regional Trends: North America and Europe are expected to be key regions driving market growth.
• Distribution Channels: E-commerce and D2C channels are transforming the distribution landscape, enhancing consumer access.
• Manufacturers: Several key companies are prominent in the market, focusing on expanding their product portfolios.

FAQs

What is the primary use of VERELAN (verapamil hydrochloride)?

VERELAN is primarily used for the treatment of hypertension, angina pectoris, and certain types of arrhythmias.

What is the projected market size of verapamil hydrochloride by 2027?

The global verapamil hydrochloride market is projected to reach USD 2.5 billion by 2027.

Which regions are expected to lead the market growth?

North America, particularly the United States, and Europe are expected to be the leading regions driving market growth.

What are the key distribution channels for verapamil hydrochloride?

E-commerce and direct-to-consumer (D2C) sales channels are significantly transforming the distribution landscape.

Who are the major manufacturers of verapamil hydrochloride?

Companies such as Bharat Pharmaceuticals, Titan Pharma, Vpl Chemicals Pvt Ltd, and others are major players in the market.

Sources

1. Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) - Not relevant to VERELAN.
2. Verapamil Hydrochloride Market Report 2024 (Global Edition) - General market report, not specific to VERELAN.
3. VERELAN - verapamil hydrochloride capsule, delayed release pellets - FDA label information.
4. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Type 1 Diabetes - JAMA article.
5. Global Verapamil Hydrochloride Market E-Commerce and Direct-to-Consumer, Sustainability - Market analysis report.